Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-11-19

Clinical Trial Update: A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis [Phase 3]

View source ↗

Summary

Phase 3 trial update for ixekizumab in biologic DMARD-naive participants with radiographic axial spondyloarthritis has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ixekizumab (ixekizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Spondyloarthritis | Phase 3 | Status: COMPLETED | Results posted: 2019-11-19